News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia
Photo of Hagop Kantarjian from mdanderson.org
Jan 18, 2024, 11:27

Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia

Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:

“Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia (R/R ALL). Study now amended to add navitoclax (BCL-xL inhibitor).”

Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia

Read further.
Source: Hagop Kantarjian/X

 

Acute Lymphoblastic Leukemia BCL-XL inhibitor cancer Hagop Kantarjian MD Anderson Cancer Center navitoclax OncoDaily Oncology venetoclax
Special Coverage
Insight
Oct 9, 2024, 12:36
Myeloma Paper of the Day, October 9th, suggested by Robert Orlowski
Blog
Oct 9, 2024, 12:28
MD Anderson Cancer Center and UICC collaborate to improve women's cancer care
Dialogues
Oct 9, 2024, 12:18
ASCO24 Updates: Dr. Daniel McFarland on Patient Portals and Oncology Communication
Blog
Oct 9, 2024, 12:05
Janet Woodcock has joined the Board of Directors of Every Cure
Blog
Oct 9, 2024, 12:04
Dana-Farber/Boston Children's ranked among the best pediatric cancer programs in the nation for 18th year in a row
Blog
Oct 9, 2024, 11:52
Addressing cancer disparities and inequalities for people with HIV - NCI Division of Cancer Control and Population Sciences
Blog
Oct 9, 2024, 11:49
The call for applications is open for the NIH/PEPFAR Local Implementation Science Network - NCI Center for Global Health
Blog
Oct 9, 2024, 11:42
Francisco J. Esteva: Rising breast cancer rates and disparities among women under 50
Insight
Oct 9, 2024, 11:40
Datopotamab Deruxtecan Trial Shows Negative OS in TROPION-Lung 01 - Panot Sainamthip
Blog
Oct 9, 2024, 11:35
Amol Akhade: The Tyranny of Non-Inferiority Trials
Blog
Oct 9, 2024, 11:30
Scientific publication on bias assessment in epidemiological studies - IARC
Blog
Oct 9, 2024, 11:08
Stereotactic Ablative Radiation trial results published in Red Journal - ESTRO